Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms

American Journal of Clinical Pathology

Volumn 124, Issue 1, 2005, Pages 11-19

  Zhang, Wanghai ^a   Hart, John ^b   McLeod, Howard L ^a   Wang, Hanlin L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Adenoma; AP 1 transcription factor; Colorectal; Neuroendocrine carcinoma

Indexed keywords

PROTEIN C JUN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR FRA 1;

ADULT; AGED; ARTICLE; CARCINOGENESIS; COLORECTAL TUMOR; CONTROLLED STUDY; CYTOPLASM; EPITHELIUM CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NEUROENDOCRINE TUMOR; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION;

EID: 21744458403     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/T1H2Y2CHWY7PD2BN     Document Type: Article

References (41)

1. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159-170.
2. Chung DC. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology. 2000;119:854-865.
3. Calland JF, Adams RB, DePrince K, et al. Genetic syndromes and genetic tests in colorectal cancer. Semin Gastrointest Dis. 2000;11:207-218.
4. Wong NA, Pignatelli M. β-Catenin: a linchpin in colorectal carcinogenesis? Am J Pathol. 2002;160:389-401.
5. Mann B, Gelos M, Siedow A, et al. Target genes of β-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A. 1999;96:1603-1608.
6. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta. 1991;1072:129-157.
7. Ozanne BW, McGarry L, Spence HJ, et al. Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer. 2000;36:1640-1648.
8. Vogt PK. Jun, the oncoprotein. Oncogene. 2001;20:2365-2377.
9. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene. 2001;20:2390-2400.
10. Jochum W, Passegué E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene. 2001;20:2401-2412.
11. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002;4:E131-E136.
12. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3:859-868.
13. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol. 1997;9:240-246.
14. Mechta-Grigoriou F, Gerald D, Yaniv M. The mammalian Jun proteins: redundancy and specificity. Oncogene. 2001;20:2378-2389.
15. Chinenov Y, Kerppola TK. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene. 2001;20:2438-2452.
16. van Dam H, Castellazzi M. Distinct roles of Jun:Fos and Jun:ATF dimers in oncogenesis. Oncogene. 2001;20:2453-2464.
17. Young MR, Yang HS, Colburn NH. Promising molecular targets for cancer prevention: AP-1, NF-κB and Pdcd4. Trends Mol Med. 2003;9:36-41.
18. Hirano F, Tanada H, Makino Y, et al. Induction of the transcription factor AP-1 in cultured human colon adenocarcinoma cells following exposure to bile acids. Carcinogenesis. 1996;17:427-433.
19. Glinghammar B, Holmberg K, Rafter J. Effects of colonic lumenal components on AP-1-dependent gene transcription in cultured human colon carcinoma cells. Carcinogenesis. 1999;20:969-976.
20. Debruyne PR, Bruyneel EA, Li X, et al. The role of bile acids in carcinogenesis. Mutat Res. 2001;480-81:359-369.
21. Qiao D, Chen W, Stratagoules ED, et al. Bile acid-induced activation of activator protein-1 requires both extracellular signal-regulated kinase and protein kinase C signaling. J Biol Chem. 2000;275:15090-15098.
22. Guo YS, Hellmich MR, Wen XD, et al. Activator protein-1 transcription factor mediates bombesin-stimulated cyclooxygenase-2 expression in intestinal epithelial cells. J Biol Chem. 2001;276:22941-22947.
23. Ferrandez A, Prescott S, Burt RW. COX-2 and colorectal cancer. Curr Pharm Des. 2003;9:2229-2251.
24. Suto R, Tominaga K, Mizuguchi H, et al. Dominant-negative mutant of c-Jun gene transfer: a novel therapeutic strategy for colorectal cancer. Gene Ther. 2004;11:187-193.
25. Akintola-Ogunremi O, Pfeifer JD, Tan BR, et al. Analysis of protein expression and gene mutation of c-kit in colorectal neuroendocrine carcinomas. Am J Surg Pathol. 2003;27:1551-1558.
26. Wang H, Birkenbach M, Hart J. Expression of Jun family members in human colorectal adenocarcinoma. Carcinogenesis. 2000;21:1313-1317.
27. Wang HL, Wang J, Xiao SY, et al. Elevated protein expression of cyclin D1 and Fra-1 but decreased expression of c-Myc in human colorectal adenocarcinomas overexpressing β-catenin. Int J Cancer. 2002;101:301-310.
28. Chida K, Nagamori S, Kuroki T. Nuclear translocation of Fos is stimulated by interaction with Jun through the leucine zipper. Cell Mol Life Sci. 1999;55:297-302.
29. Monnat M, Tardy S, Saraga P, et al. Prognostic implications of expression of the cellular genes myc, fos, Ha-ros and Ki-ras in colon carcinoma. Int J Cancer. 1987;40:293-299.
30. Untawale S, Blick M. Oncogene expression in adenocarcinomas of the colon and in colon tumor-derived cell lines. Anticancer Res. 1988;8:1-7.
31. Sugio K, Kurata S, Sasaki M, et al. Differential expression of c-myc gene and c-fos gene in premalignant and malignant tissues from patients with familial polyposis coli. Cancer Res. 1988;48:4855-4861.
32. Imaseki H, Hayashi H, Taira M, et al. Expression of c-myc oncogene in colorectal polyps as a biological marker for monitoring malignant potential. Cancer. 1989;64:704-709.
33. Klimpfinger M, Zisser G, Ruhri C, et al. Expression of c-myc and c-fos mRNA in colorectal carcinoma in man. Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;59:165-171.
34. Nagai MA, Habr-Gama A, Oshima CT, et al. Association of genetic alterations of c-myc, c-fos, and c-Ha-ras proto-oncogenes in colorectal tumors: frequency and clinical significance. Dis Colon Rectum. 1992;35:444-451.
35. Foletta VC. Transcription factor AP-1, and the role of Fra-2. Immunol Cell Biol. 1996;74:121-133.
36. McHenry JZ, Leon A, Matthaei KI, et al. Overexpression of fra-2 in transgenic mice perturbs normal eye development. Oncogene. 1998;17:1131-1140.
37. Tulchinsky E. Fos family members: regulation, structure and role in oncogenic transformation. Histol Histopathol. 2000;15:921-928.
38. Bakiri L, Matsuo K, Wisniewska M, et al. Promoter specificity and biological activity of tethered AP-1 dimers. Mol Cell Biol. 2002;22:4952-4964.
39. Vortmeyer AO, Lubensky IA, Merino MJ, et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst. 1997;89:1448-1453.
40. Sagara M, Sugiyama F, Horiguchi H, et al. Activation of the nuclear oncogenes N-myc and c-jun in carcinoid tumors of transgenic mice carrying the human adenovirus type 12 E1 region gene. DNA Cell Biol. 1995;14:95-101.
41. Wang DG, Johnston CF, Buchanan KD. Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications for pathogenesis. Cancer. 1997;80:668-675.